Allan J. Pantuck active positions
| Companies | Position | Start | End |
|---|---|---|---|
Athos Therapeutics, Inc.
 Athos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then. | Chairman | 17/04/2019 | - |
| Chief Tech/Sci/R&D Officer | 17/04/2019 | - | |
| Founder | 17/04/2019 | - |
Career history of Allan J. Pantuck
Statistics
International
| United States | 2 |
Operational
| Chairman | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectoral
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Athos Therapeutics, Inc.
Athos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then. | Health Technology |
- Stock Market
- Insiders
- Allan J. Pantuck
- Experience
